CALCIMEDICA INC (CALC) Stock Fundamental Analysis

NASDAQ:CALC • US38942Q2021

0.552 USD
+0.01 (+1.85%)
At close: Feb 26, 2026
0.56 USD
+0.01 (+1.45%)
After Hours: 2/26/2026, 8:13:50 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

Taking everything into account, CALC scores 1 out of 10 in our fundamental rating. CALC was compared to 192 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of CALC have multiple concerns. CALC does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year CALC has reported negative net income.
  • In the past year CALC has reported a negative cash flow from operations.
  • CALC had negative earnings in each of the past 5 years.
  • In the past 5 years CALC always reported negative operating cash flow.
CALC Yearly Net Income VS EBIT VS OCF VS FCFCALC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M

1.2 Ratios

  • CALC has a Return On Assets of -154.63%. This is amonst the worse of the industry: CALC underperforms 85.42% of its industry peers.
Industry RankSector Rank
ROA -154.63%
ROE N/A
ROIC N/A
ROA(3y)-146.96%
ROA(5y)-105.36%
ROE(3y)-205.06%
ROE(5y)-141.38%
ROIC(3y)N/A
ROIC(5y)N/A
CALC Yearly ROA, ROE, ROICCALC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for CALC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CALC Yearly Profit, Operating, Gross MarginsCALC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. Health

2.1 Basic Checks

  • Compared to 1 year ago, CALC has more shares outstanding
  • Compared to 5 years ago, CALC has more shares outstanding
  • CALC has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CALC Yearly Shares OutstandingCALC Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
CALC Yearly Total Debt VS Total AssetsCALC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • CALC has an Altman-Z score of -21.07. This is a bad value and indicates that CALC is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -21.07, CALC is doing worse than 83.33% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -21.07
ROIC/WACCN/A
WACCN/A
CALC Yearly LT Debt VS Equity VS FCFCALC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 4.04 indicates that CALC has no problem at all paying its short term obligations.
  • CALC has a Current ratio of 4.04. This is comparable to the rest of the industry: CALC outperforms 59.90% of its industry peers.
  • CALC has a Quick Ratio of 4.04. This indicates that CALC is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of CALC (4.04) is better than 61.98% of its industry peers.
Industry RankSector Rank
Current Ratio 4.04
Quick Ratio 4.04
CALC Yearly Current Assets VS Current LiabilitesCALC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

0

3. Growth

3.1 Past

  • CALC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -53.70%.
EPS 1Y (TTM)-53.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • CALC is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -20.31% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-41.18%
EPS Next 2Y-14.1%
EPS Next 3Y-20.31%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CALC Yearly Revenue VS EstimatesCALC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2M 4M 6M
CALC Yearly EPS VS EstimatesCALC Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 -10 -20 -30 -40 -50

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • CALC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CALC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CALC Price Earnings VS Forward Price EarningsCALC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CALC Per share dataCALC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1 -1.5

4.3 Compensation for Growth

  • A cheap valuation may be justified as CALC's earnings are expected to decrease with -20.31% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.1%
EPS Next 3Y-20.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for CALC!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CALCIMEDICA INC

NASDAQ:CALC (2/26/2026, 8:13:50 PM)

After market: 0.56 +0.01 (+1.45%)

0.552

+0.01 (+1.85%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-12
Earnings (Next)03-25
Inst Owners55.61%
Inst Owner Change3.02%
Ins Owners18.57%
Ins Owner Change0%
Market Cap7.95M
Revenue(TTM)N/A
Net Income(TTM)-23.06M
Analysts82
Price Target16.66 (2918.12%)
Short Float %6.37%
Short Ratio0.54
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-17.82%
Min EPS beat(2)-23.59%
Max EPS beat(2)-12.04%
EPS beat(4)0
Avg EPS beat(4)-14.1%
Min EPS beat(4)-23.59%
Max EPS beat(4)-5.69%
EPS beat(8)4
Avg EPS beat(8)19.19%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.51%
PT rev (3m)2.08%
EPS NQ rev (1m)-25%
EPS NQ rev (3m)-8.55%
EPS NY rev (1m)-5.09%
EPS NY rev (3m)-8.61%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.66
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-1.48
FCFYN/A
OCF(TTM)-1.48
OCFYN/A
SpS0
BVpS-0.02
TBVpS-0.02
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -154.63%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-146.96%
ROA(5y)-105.36%
ROE(3y)-205.06%
ROE(5y)-141.38%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.04
Quick Ratio 4.04
Altman-Z -21.07
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)79.82%
Cap/Depr(5y)117.74%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.7%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-4%
EPS Next Y-41.18%
EPS Next 2Y-14.1%
EPS Next 3Y-20.31%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-11.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-21.96%
EBIT Next 3Y-13.69%
EBIT Next 5YN/A
FCF growth 1Y21.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y21.66%
OCF growth 3YN/A
OCF growth 5YN/A

CALCIMEDICA INC / CALC FAQ

What is the ChartMill fundamental rating of CALCIMEDICA INC (CALC) stock?

ChartMill assigns a fundamental rating of 1 / 10 to CALC.


Can you provide the valuation status for CALCIMEDICA INC?

ChartMill assigns a valuation rating of 0 / 10 to CALCIMEDICA INC (CALC). This can be considered as Overvalued.


What is the profitability of CALC stock?

CALCIMEDICA INC (CALC) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CALCIMEDICA INC?

The Earnings per Share (EPS) of CALCIMEDICA INC (CALC) is expected to decline by -41.18% in the next year.